Form 4: Ionis CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals CEO Brett P. Monia sold 437 shares of common stock for $69.2637 per share on October 6, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Brett P. Monia, Chief Executive Officer and Director of IONIS PHARMACEUTICALS INC, reported a sale of common stock.
- The transaction occurred on October 6, 2025.
- A total of 437 shares of common stock were disposed of.
- The shares were sold at a price of $69.2637 per share.
- Following this transaction, Brett P. Monia beneficially owns 179,572 shares of common stock directly.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on August 13, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine, pre-planned insider stock sale under a 10b5-1 plan, which typically does not reflect new fundamental information about the company's performance or prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects a personal financial decision by a company executive.
Key Dates
| Date | Description |
|---|---|
| 2024-08-13 | Date Rule 10b5-1 Trading Plan was adopted by Brett P. Monia. |
| 2025-10-06 | Date of common stock transaction (sale of 437 shares). |
| 2025-10-08 | Date the Form 4 was signed by attorney-in-fact for Brett P. Monia. |
Recommendation
holdThis Form 4 filing reports a routine, pre-scheduled insider sale of a relatively small number of shares by the CEO under a 10b5-1 trading plan. Such transactions are typically personal financial management decisions and do not provide new material information about the company's operational performance, strategic direction, or financial health. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Ionis Pharmaceuticals, IONS, Brett P. Monia, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.